Review





Similar Products

human miltenyi biotec  (Miltenyi Biotec)
94
Miltenyi Biotec human miltenyi biotec
Human Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd1c/pm41997138-350-266-267?v=Miltenyi+Biotec
Average 94 stars, based on 1 article reviews
human miltenyi biotec - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
cd1c  (Huabio Inc)
86
Huabio Inc cd1c
TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
Cd1c, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd1c/pmc13253696-70-20-21?v=Huabio+Inc
Average 86 stars, based on 1 article reviews
cd1c - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
cflour r668 anti human cd1c  (Cytek Biosciences)
94
Cytek Biosciences cflour r668 anti human cd1c
TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
Cflour R668 Anti Human Cd1c, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd1c/pmc12964223-35-0-7?v=Cytek+Biosciences
Average 94 stars, based on 1 article reviews
cflour r668 anti human cd1c - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
anti human cd1c bdca1  (Miltenyi Biotec)
95
Miltenyi Biotec anti human cd1c bdca1
TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
Anti Human Cd1c Bdca1, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd1c/pm41707448-99-118-125?v=Miltenyi+Biotec
Average 95 stars, based on 1 article reviews
anti human cd1c bdca1 - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
miltenyi biotech cd1c  (Miltenyi Biotec)
94
Miltenyi Biotec miltenyi biotech cd1c
TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
Miltenyi Biotech Cd1c, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd1c/pm41604686-80-19-19?v=Miltenyi+Biotec
Average 94 stars, based on 1 article reviews
miltenyi biotech cd1c - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
human cd1c bdca1 dendritic cell isolation kit  (Miltenyi Biotec)
94
Miltenyi Biotec human cd1c bdca1 dendritic cell isolation kit
TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
Human Cd1c Bdca1 Dendritic Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd1c/pm41344082-102-8-16?v=Miltenyi+Biotec
Average 94 stars, based on 1 article reviews
human cd1c bdca1 dendritic cell isolation kit - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
cd1c  (Miltenyi Biotec)
94
Miltenyi Biotec cd1c
TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
Cd1c, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd1c/10__1021_slash_acsomega__5c06105-60-18-24?v=Miltenyi+Biotec
Average 94 stars, based on 1 article reviews
cd1c - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
umab61  (OriGene)
93
OriGene umab61
TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
Umab61, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd1c/us12472252-171-46-47?v=OriGene
Average 93 stars, based on 1 article reviews
umab61 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
cd1c (bdca-1) antibody, anti-human, pe  (Miltenyi Biotec)
95
Miltenyi Biotec cd1c (bdca-1) antibody, anti-human, pe
TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
Cd1c (Bdca 1) Antibody, Anti Human, Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd1c/custom%40130-113-864%4040986321?v=Miltenyi+Biotec
Average 95 stars, based on 1 article reviews
cd1c (bdca-1) antibody, anti-human, pe - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

Image Search Results


TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, CD1c, CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.

Journal: Frontiers in Immunology

Article Title: Tumor immune microenvironment states inferred from TLS-associated immune-cell composition stratify prognosis in hepatocellular carcinoma

doi: 10.3389/fimmu.2026.1818138

Figure Lengend Snippet: TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, CD1c, CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.

Article Snippet: The antibody panel included CD45 (Aifang, AF20018), CD4 (Aifang, AF20210), FOXP3 (Maxim, MAB-1004), CD11c (Aifang, AF20381), CD21 (Aifang, AF20013), and CD1c (HUABIO, HA722562), each used at 1:200.

Techniques: Spatial Transcriptomics, Multiplex Assay, Immunofluorescence, Staining, Derivative Assay